

## DESCRIPTION


<b>Species Reactivity</b>	Human
<b>Specificity</b>	Detects human Dectin-2/CLEC6A in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant mouse Dectin-2 $\alpha$ , recombinant human (rh) CLEC9A, rhCLEC4D, or rhDLEC is observed.
<b>Source</b>	Monoclonal Mouse IgG <sub>1</sub> Clone # 545943
<b>Purification</b>	Protein A or G purified from hybridoma culture supernatant
<b>Immunogen</b>	Mouse myeloma cell line NS0-derived recombinant human Dectin-2/CLEC6A Thr46-Leu209 Accession # Q6EIG7
<b>Formulation</b>	Lyophilized from a 0.2 $\mu$ m filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 $\mu$ m filtered solution in PBS.

## APPLICATIONS

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	Recommended Concentration	Sample
<b>Flow Cytometry</b>	2.5 $\mu$ g/10 <sup>6</sup> cells	See Below
<b>CyTOF-ready</b>	Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.	

## DATA



## PREPARATION AND STORAGE

<b>Reconstitution</b>	Reconstitute at 0.5 mg/mL in sterile PBS.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
<b>Stability &amp; Storage</b>	<b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b> <ul style="list-style-type: none"> <li>● 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>● 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>● 6 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>

**BACKGROUND**

Dectin-2, also known as CLEC6A, CLECSF10, and NKCL, belongs to the C-type lectin family of transmembrane immune regulatory glycoproteins. Dectin-2, plus CLEC4A-E constitute a subgroup of molecules that exhibit approximately 40% amino acid (aa) sequence identity in their extracellular domains (ECD), and have a conserved cysteine spacing in their carbohydrate recognition domains (CRD) (1, 2). Mature human Dectin-2 is a type II transmembrane protein with a short cytoplasmic tail, a transmembrane segment, and a 168 aa ECD with a stalk region and one CRD (3, 4). Within the ECD, human Dectin-2 shares 71% and 75% aa sequence identity with bovine and mouse Dectin-2, respectively. An alternately spliced  $\beta$  isoform has a deletion of portions of the transmembrane and cytoplasmic regions (5). Full length Dectin-2 is a 27 kDa molecule that is expressed on monocytes, tissue macrophages, and activated CD4<sup>+</sup> T cells (4-6). The CRD of Dectin-2 contains an EPN motif which is characteristic of calcium-dependent mannose-binding lectins. Dectin-2 selectively interacts with high mannose structures in the Man<sub>3</sub>GlcNAc<sub>2</sub> configuration (7). It mediates the recognition of a variety of microorganisms, particularly the filamentous forms of yeast and fungi (7, 8). The short cytoplasmic tail does not contain signaling motifs but mediates association with the ITAM-containing Fc receptor  $\gamma$  subunit on macrophages (8). Ligation of Dectin-2 induces tyrosine phosphorylation of the  $\gamma$  subunit, activation of NF $\kappa$ B, and enhanced release of TNF- $\alpha$  and IL-1ra (8). Macrophage Dectin-2 is up-regulated *in vivo* by inflammatory stimuli and UV-B irradiation (5, 6, 9). Dectin-2 is known to participate in UV-induced immunosuppression by interacting with CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells, which then induce dendritic cells to release IL-4, IL-10, and TGF- $\beta$  (10).

**References:**

1. Kanazawa, N. (2007) *J. Dermatol. Sci.* **45**:77.
2. Kanazawa, N. *et al.* (2004) *Immunobiology* **209**:179.
3. Flornes, L.M. *et al.* (2004) *Immunogenetics* **56**:506.
4. Kanazawa, N. *et al.* (2004) *J. Invest. Dermatol.* **122**:1522.
5. Gavino, A.C. *et al.* (2005) *Exp. Dermatol.* **14**:281.
6. Taylor, P.R. *et al.* (2005) *Eur. J. Immunol.* **35**:2163.
7. McGreal, E.P. *et al.* (2006) *Glycobiology* **16**:422.
8. Sato, K. *et al.* (2006) *J. Biol. Chem.* **281**:38854.
9. Bonkobara, M. *et al.* (2005) *Photochem. Photobiol.* **81**:944.
10. Aragane, Y. *et al.* (2003) *J. Immunol.* **171**:3801.